Search

Search Constraints

You searched for: Author/Creator Egle, Alexander

Search Results

21. Quality of life in patients with relapsed/refractory multiple myeloma during ixazomib-thalidomide-dexamethasone induction and ixazomib maintenance therapy and comparison to the general population. Issue 2 (28th January 2020)

22. Reduced alpha diversity of the oral microbiome correlates with short progression‐free survival in patients with relapsed/refractory multiple myeloma treated with ixazomib‐based therapy (AGMT MM 1, phase II trial). Issue 1 (8th November 2020)

23. Remdesivir plus standard of care versus standard of care alone for the treatment of patients admitted to hospital with COVID-19 (DisCoVeRy): a phase 3, randomised, controlled, open-label trial. Issue 2 (February 2022)

25. Rituximab maintenance overcomes the negative prognostic factor of obesity in CLL: Subgroup analysis of the international randomized AGMT CLL‐8a mabtenance trial. (19th March 2019)

26. Rituximab maintenance versus observation alone in patients with chronic lymphocytic leukaemia who respond to first-line or second-line rituximab-containing chemoimmunotherapy: final results of the AGMT CLL-8a Mabtenance randomised trial. Issue 7 (July 2016)

27. Similar But Different: Integrated Phylogenetic Analysis of Austrian and Swiss HIV-1 Sequences Reveal Differences in Transmission Patterns of the Local HIV-1 Epidemics. (1st August 2022)

28. The AKT1 isoform plays a dominant role in the survival and chemoresistance of chronic lymphocytic leukaemia cells. (6th July 2015)

29. The clinical significance of fibrinogen plasma levels in patients with diffuse large B cell lymphoma. Issue 4 (7th December 2015)

30. The significance of pretreatment anemia in the era of R‐IPI and NCCN‐IPI prognostic risk assessment tools: a dual‐center study in diffuse large B‐cell lymphoma patients. (26th March 2015)